Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.
Fighting the Hype for Predictors of Efficacy in Inflammatory Bowel Disease
Lopetuso, L. R.
;
2020-01-01
Abstract
Primary or secondary nonresponse to anti-TNF-alpha due to immunogenicity or treatment-related side effects and the growing presence of innovative biological therapies targeting different cytokines and immune processes raise a clear need for predictors of efficacy for anti-TNF-alpha treatment.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
izz274.pdf
Solo gestori archivio
Descrizione: Editorial
Tipologia:
PDF editoriale
Dimensione
86.62 kB
Formato
Adobe PDF
|
86.62 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
